National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

EGFR/HER2 inhibitor AV-412
A second-generation, orally bioavailable dual kinase inhibitor with potential antineoplastic activity. EGFR/HER2 inhibitor AV-412 binds to and inhibits the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2), which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. This agent may be active against EGFR/HER2-expressing tumor cells that are resistant to first-generation kinase inhibitors. EGFR and HER2 are receptor tyrosine kinases that play major roles in tumor cell proliferation and tumor vascularization. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:AV-412



Previous:eflornithine hydrochloride ointment, Efudex, EGb761, EGEN-001, EGFR antisense DNA
Next:EGFR/HER2 tyrosine kinase inhibitor BIBW 2992, EGFRBi-armed autologous activated T cells, eicosapentaenoic acid, EKB-569, EL625

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov